Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Willand

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Scientific Reports|May 12, 2018
Publisher Correction: Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticlesJoana Costa-Gouveia, Elisabetta Pancani, Samuel Jouny, et al.
Scientific Reports|July 16, 2017
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticlesJoana Costa-Gouveia, Elisabetta Pancani, Samuel Jouny, et al.
European Journal of Medicinal Chemistry|June 7, 2020
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screeningLéo Faïon, Kamel Djaout, Rosangela Frita, et al.
Journal of Medicinal Chemistry|November 22, 2011
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitorsMarion Flipo, Matthieu Desroses, Nathalie Lecat-Guillet, et al.
EMBO Molecular Medicine|January 4, 2024
Pyridylpiperazine efflux pump inhibitor boosts in vivo antibiotic efficacy against K. pneumoniaeAnais Vieira Da Cruz, Juan-Carlos Jiménez-Castellanos, Clara Börnsen, et al.
Nature Communications|January 11, 2022
Pyridylpiperazine-based allosteric inhibitors of RND-type multidrug efflux pumpsColine Plé, Heng-Keat Tam, Anais Vieira Da Cruz, et al.
Antimicrobial Agents and Chemotherapy|July 13, 2026
<i>In vitro</i> characterization of GSK2556286 in combination with bedaquiline and pretomanid against <i>Mycobacterium tuberculosis</i>Marie Sylvianne Rabodoarivelo, Jordana Galizia, Deborah Recchia, et al.
Science (New York, N.Y.)|March 18, 2017
Reversion of antibiotic resistance in <i>Mycobacterium tuberculosis</i> by spiroisoxazoline SMARt-420Nicolas Blondiaux, Martin Moune, Matthieu Desroses, et al.
Npj Antimicrobials and Resistance|May 30, 2026
Exploiting DprE2 pathway redundancy to enhance potency and overcome resistance to pretomanid in Mycobacterium tuberculosisKamel Djaout, Aurore Dreneau, Léo Faion, et al.
ACS Nano|March 2, 2019
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against TuberculosisArnaud Machelart, Giuseppina Salzano, Xue Li, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Scientific Reports|May 12, 2018
Publisher Correction: Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticlesJoana Costa-Gouveia, Elisabetta Pancani, Samuel Jouny, et al.
Scientific Reports|July 16, 2017
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticlesJoana Costa-Gouveia, Elisabetta Pancani, Samuel Jouny, et al.
European Journal of Medicinal Chemistry|June 7, 2020
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screeningLéo Faïon, Kamel Djaout, Rosangela Frita, et al.
Journal of Medicinal Chemistry|November 22, 2011
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitorsMarion Flipo, Matthieu Desroses, Nathalie Lecat-Guillet, et al.
EMBO Molecular Medicine|January 4, 2024
Pyridylpiperazine efflux pump inhibitor boosts in vivo antibiotic efficacy against K. pneumoniaeAnais Vieira Da Cruz, Juan-Carlos Jiménez-Castellanos, Clara Börnsen, et al.
Nature Communications|January 11, 2022
Pyridylpiperazine-based allosteric inhibitors of RND-type multidrug efflux pumpsColine Plé, Heng-Keat Tam, Anais Vieira Da Cruz, et al.
Antimicrobial Agents and Chemotherapy|July 13, 2026
<i>In vitro</i> characterization of GSK2556286 in combination with bedaquiline and pretomanid against <i>Mycobacterium tuberculosis</i>Marie Sylvianne Rabodoarivelo, Jordana Galizia, Deborah Recchia, et al.
Science (New York, N.Y.)|March 18, 2017
Reversion of antibiotic resistance in <i>Mycobacterium tuberculosis</i> by spiroisoxazoline SMARt-420Nicolas Blondiaux, Martin Moune, Matthieu Desroses, et al.
Npj Antimicrobials and Resistance|May 30, 2026
Exploiting DprE2 pathway redundancy to enhance potency and overcome resistance to pretomanid in Mycobacterium tuberculosisKamel Djaout, Aurore Dreneau, Léo Faion, et al.
ACS Nano|March 2, 2019
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against TuberculosisArnaud Machelart, Giuseppina Salzano, Xue Li, et al.
Pageof 6